uniQure N.V. - Ordinary Shares (QURE)

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,

Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.

The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke.

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.